Lexicon Pharmaceuticals (LXRX) Current Assets (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Current Assets data on file, last reported at $186.0 million in Q1 2026.

• Current Assets for Q1 2026 came in at $186.0 million, down 24.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $186.0 million (down 24.32% YoY), and the FY2025 annual result was $101.9 million, down 58.61% from the prior year.
• Current Assets rose to $186.0 million in Q1 2026 per LXRX's latest filing, from $101.9 million in the prior quarter.
• Over five years, Current Assets peaked at $364.6 million in Q1 2024 and troughed at $64.9 million in Q2 2022.
• A 5-year average of $188.7 million and a median of $176.5 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets jumped 306.36% in 2023, then slumped 58.61% in 2025.
• A 5-year view of Current Assets shows it stood at $140.9 million in 2022, then increased by 25.33% to $176.5 million in 2023, then jumped by 39.45% to $246.2 million in 2024, then slumped by 58.61% to $101.9 million in 2025, then soared by 82.57% to $186.0 million in 2026.
• Business Quant data shows LXRX's Current Assets at $186.0 million in Q1 2026, $101.9 million in Q4 2025, and $122.5 million in Q3 2025.